(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau





(10) International Publication Number WO 2016/123418 A1

(43) International Publication Date 4 August 2016 (04.08.2016)

(51) International Patent Classification:

C08F 230/08 (2006.01) A61K 47/32 (2006.01)

C08F 220/10 (2006.01)

(21) International Application Number:

PCT/US2016/015500

(22) International Filing Date:

29 January 2016 (29.01.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) **Priority Data**: 62/109,415

0994 (US).

29 January 2015 (29.01.2015) US

- (71) Applicant: DOW CORNING CORPORATION
 [US/US]; 2200 West Salzburg Road, Midland, MI 48686-
- (72) Inventors: HUBER, Robert, O.; 819 Airfield Lane, Midland, MI 48642 (US). LOUBERT, Gary, Lee; 6828 Mccarty Road, Saginaw, MI 48603 (US). SCHALAU, Gerald, K., II.; 504 East Dawn Drive, Freeland, MI 48623 (US). TOTH, Simon; 5007 Goldenwood Drive, Midland, MI 48640 (US).
- (74) Agent: TROY, Timothy, J.; Dow Corning Corporation, Patent Department - CO2200, 2200 West Salzburg Road, Midland, MI 48686-0994 (US).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: SILICONE ACRYLATE COMPOSITIONS AND METHODS OF PREPARING THE SAME




FIGURE 1

(57) Abstract: Silicone acrylate copolymer composition, namely, silicone resin-acrylate copolymers and methods of preparing the same. The silicone acrylate composition may include a silicone resin coupled with an acrylate polymer via a linking group. The silicone acrylate composition may be formed by preparing an acrylate or a (meth)acrylate functional resin and carrying out acrylate polymerization in the presence of a functionalized resin. A silane- functional acrylate polymer may be prepared, followed by a reaction to couple a resin to the silane-functional acrylate polymer. The resulting copolymer may then be used as desired, e.g., added to a silicone and acrylate mixture to create a nonseparating blend.







— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

SILICONE ACRYLATE COMPOSITIONS AND METHODS OF PREPARING THE SAME

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] None

BRIEF SUMMARY OF THE INVENTION

[0002] The embodiments described herein relate to silicone acrylate copolymer compositions. More specifically, the embodiments described herein relate to silicone resinacrylate copolymers and methods of preparing the same.

BRIEF DESCRIPTION OF THE DRAWINGS

[0003] Various advantages of the invention will become apparent upon reading the following detailed description and upon reference to the drawings.

[0004] FIG. 1 is a graph showing the estradiol flux of compositions according to embodiments described herein.

[0005] While the invention is susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and will be described in detail herein. It should be understood, however, that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.

DETAILED DESCRIPTION OF THE INVENTION

[0006] The embodiments described herein are directed toward silicone acrylate copolymer compositions and methods of preparing the same. The silicone acrylate compositions may be used in a variety of applications, including pressure sensitive adhesives (PSAs), film formers, PSA additives, as compatibilizing agents for assisting in creating stable, non-separating silicone and acrylic adhesive blends, and the like. The silicone acrylate copolymer compositions may generally be used alone or in wide ranges of mixing ratios and addition levels with PSAs to act as a PSA, film former, PSA additive, and/or compatibilizing agent. Blends of silicone pressure sensitive adhesives (PSAs) and acrylic polymers in a transdermal drug delivery system may assist in optimizing the solubility of an active agent, thereby creating a system with increased drug delivery efficiency. However, because the blends are generally thermodynamically unstable, undesirable gross phase separation typically occurs upon drying of the adhesives.

[0007] According to one embodiment, a silicone acrylate composition includes a silicone resin coupled with an acrylate polymer via a linking group. The silicone acrylate composition may be formed by preparing an acrylate or a (meth)acrylate functional resin and carrying out acrylate polymerization in the presence of a functionalized resin. In another embodiment, a silane-functional acrylate polymer may be prepared, followed by a reaction to couple a resin

1

to the silane-functional acrylate polymer. The resulting copolymer may then be used as desired, e.g., added to a silicone and acrylate mixture to create a non-separating blend.


[0008] According to one embodiment, a silicone acrylate composition has a general formula

as follows:
$$R^2$$
 R^3 R^4 R^4

hydrogen or methyl, and each R² and R³ is independently selected from hydrogen or methyl, and each R² and R³ is independently selected from hydrogen, hydrogen alkyls, branched alkyls, methyl, ethyl, propyl, n-butyl, iso-butyl, tert-butyl, hexyl, 2-ethylhexyl, iso-octyl, iso-nonyl, iso-pentyl, tridecyl, stearyl, lauryl, hydroxyethyl acetate, (hydroxyethyl)methacrylate, methacrylate esters, acrylate esters, and any combination

 $\begin{matrix} & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\$

thereof. Each R^4 is a silane having the general formula R^7 , wherein R^5 is selected from -(CH₂)_z-, -(CH₂)₃-NH-C(=O)-O-CH₂-CH₂-, -(CH₂)₃-NH-CH₂-CH(OH)-CH₂-, and -OCH₂-CH₂-, and each R^6 , R^7 , and R^8 is independently selected from C1-C12 alkyl, -O-(Si-O)p-Si(CH₃)₃ where p is from 0-1000, phenyl, and -(CH₂)_n-CH=CH₂ where n is between 0 and 6.



 R^4 of Formula I or Formula II may have the formula . The silicone acrylate composition of Formula I or Formula II may include between about 0-99% w/w x groups, between about 0-99% w/w y groups, between about 0-20% w/w s groups, and between about 1-80% w/w r groups. The % w/w of at least one of the x groups and the y groups is not zero.

[0009] Each R of Formula I or Formula II may be a silsesquioxane having the general formula $[(R^9)_2R^{10}SiO_{1/2}]_a[SiO_{4/2}]_q[R^{11}SiO_{3/2}]_t[(R^{12})_3SiO_{1/2}]_m$, where R⁹ is selected from C1-C12 alkyl, -O-(Si-O)p-Si(CH₃)₃ where p is from 0-200, phenyl, and -(CH₂)_n-CH=CH₂ where n is

between 0 and 6. R^{10} is selected from -(CH_2)_z-, -(CH_2)₃-NH-C(=O)-O-CH₂-CH₂-, -(CH_2)₃-NH-C(H₂-CH₂-, and -OCH₂-CH₂-. R^{10} is selected from acrylate functional silanes, acrylate functional disilazanes, acrylate functional disilazanes, acrylate functional disilazanes, methacrylate functional disilazanes, methacrylate functional disilazanes, methacrylate functional disilazanes, methacrylate functional disilazanes, and any combination(s) thereof. R^{11} is selected from phenyl, C1-C12 alkyl, -OH, isopropoxy, -(CH_2)_n-CH=CH₂ where n is between 0 and 6. R^{12} is selected from C1-C12 alkyl. In one embodiment, a is from 1 to 5 per R unit, q is from 1 to 300, t is from 0-300, m is from 4-300, and the ratio of m/q is between about 10/90 to about 90/10. In one embodiment, a is 1.

[0010] According to another embodiment, a thermodynamically stable silicone acrylate blend composition includes (a) a silicone acrylate composition of Formula I or Formula II; (b) a silicone PSA; and (c) an acrylic polymer. The silicone acrylate blend composition lacks covalent bonds between the silicone acrylate copolymer and the silicone PSA or the acrylic polymer. The silicone PSA may be selected from amine-compatible silicone adhesives and any combination(s) thereof. In one non-limiting embodiment, the silicone PSA has the general formula $[SiO_{4/2}]_g[R^{13}SiO_{3/2}]_h[(R^{14})_3SiO_{1/2}]_i[(R^{14})_3SiO_{2/2}]_d$, wherein R^{13} is -OH, isopropoxy, or the combination(s) thereof, and R^{14} is C1-C12 alkyl. In one embodiment, g may be between about 5-50 mol%, h may be between about 0.1-20 mol%, i may be between about 5-50 mol%, d may be between about 5-90%, and the weight ratio of (g+h+i)/d may be between about 10/90 to about 90/10.

[0011] According to another embodiment, a thermodynamically stable silicone acrylate blend composition includes (a) a silicone acrylate composition of Formula I or Formula II, and (b) a silicone PSA. The silicone acrylate blend composition lacks covalent bonds between the silicone acrylate composition and the silicone PSA. The silicone PSA may be selected from amine-compatible silicone adhesives and any combination(s) thereof. The silicone PSA may have the general formula $[SiO_{4/2}]_g[R^{13}SiO_{3/2}]_h[(R^{14})_3SiO_{1/2}]_i[(R^{14})_3SiO_{2/2}]_d$, wherein R^{13} is -OH, isopropoxy, or the combination(s) thereof, and R^{14} is C1-C12 alkyl. In one embodiment, g may be between about 5-50 mol%, h may be between about 0.1-20 mol%, i may be between about 5-50 mol%, d may be between about 5-90%, and the weight ratio of (g+h+i)/d may be between about 10/90 to about 90/10.

[0012] The methods described herein may incorporate the use of any suitable types of catalysts or combination(s) thereof. The catalyst(s) may be selected from peroxide, azo compounds, 2,2'-azobis(2-methylbutyronitrile), alkyl borane catalysts, any combination(s) thereof, and the like. If the catalyst is an alkyl borane catalyst, the preparation of the acrylic polymer may take place at ambient conditions. If the catalyst is a peroxide or azo compound,

the preparation of the silicone acrylic composition may take place at an elevated temperature of between above room temperature and about 100 °C.

[0013] The silicone PSA of the embodiments described herein may be silanol-functional or capped with hexamethyldisilazane. Alternatively, the PSA may include those described in U.S. Patent No. 4,655,767, which is incorporated by reference herein. Specifically, the PSA may include a blend of a chemically-treated silicone PSA composition with less than about 30 wt% based on nonvolatile solids content of a chemically-treated modifier comprising from 1 to 100 parts by weight of a silicone resin copolymer consisting essentially of R₃ SiO_{1/2} units and SiO_{4/2} units in a mole ratio of from 0.6 to 0.9 R₃ SiO_{1/2} units for each SiO_{4/2} unit present and from 0 to 99 parts by weight of at least one polydiorganosiloxane consisting essentially of ARSiO units terminated with endblocking TRASiO_{1/2} units, each said polydiorganosiloxane having a viscosity of from 100 centipoise to 30,000,000 centipoise at 25° C.

[0014] The acrylic polymer of the embodiments described herein may be an acrylic polymer compound selected from aliphatic acrylates, aliphatic methacrylates, cycloaliphatic acrylates, cycloaliphatic methacrylates, acrylamides, methacrylamides, hydroxy-functional (meth)acrylates, carboxy-functional (meth)acrylates, and any combination(s) thereof. Each of the acrylic polymer compounds may have up to 20 carbon atoms in the alkyl radical. The aliphatic acrylates may be selected from methyl acrylate (MA), ethyl acrylate, propyl acrylate, n-butyl acrylate, iso-butyl acrylate, tert-butyl acrylate, hexyl acrylate, 2-ethylhexyl acrylate (EHA), iso-octyl acrylate, iso-nonyl acrylate, iso-pentyl acrylate, tridecyl acrylate, stearyl acrylate, lauryl acrylate, and any combination(s) thereof. The aliphatic methacrylates may be selected from methyl methacrylate, ethyl methacrylate, propyl methacrylate, n-butyl methacrylate, iso-butyl methacrylate, tert-butyl methacrylate, hexyl methacrylate, 2ethylhexyl methacrylate, iso-octyl methacrylate, iso-nonyl methacrylate, iso-pentyl methacrylate, tridecyl methacrylate, stearyl methacrylate, lauryl methacrylate, acrylamides, may be selected from methyl acrylamide, ethyl acrylamide propyl acrylamide, isopropyl acrylamide n-butyl acrylamide, iso-butyl acrylamide, tert-butyl acrylamide, hexyl acrylamide, 2-ethylhexyl acrylamide, iso-octyl acrylamide, iso-nonyl acrylamide, iso-pentyl acrylamide, tridecyl acrylamide, stearyl acrylamide, lauryl acrylamide, and any combination(s) thereof. methacrylamides, may be selected from methyl methacrylamide, ethyl methacrylamide, propyl methacrylamide, isopropyl methacrylamide, n-butyl methacrylamide, iso-butyl methacrylamide, methacrylamide, tert-butyl hexyl methacrylamide, 2-ethylhexyl methacrylamide, iso-octyl methacrylamide, iso-nonyl methacrylamide, iso-pentyl methacrylamide,, tridecyl methacrylamide, stearyl methacrylamide, lauryl methacrylamide, hydroxy-functional (meth)acrylates, carboxy-functional (meth)acrylates and any combination(s) thereof.

[0015] A transdermal drug delivery system, according to one embodiment, may include a silicone acrylate composition of the embodiments described herein and an active agent for controlled transdermal delivery to a substrate. The transdermal drug delivery system may optionally include penetration enhancers and/or polymers configured to prevent crystallization of the active agent.

[0016] In addition to active agent and silicone-based excipients, various excipients and/or enhancing agents may be incorporated into the topical formulation. As generally understood by those skilled in the art, excipients are additives that are used to convert the active agent into appropriate dosage forms that are suitable for application to the substrate. Excipients may also be added to stabilize the formulation and to optimize application characteristics, such as flowability.

[0017] Examples of potential excipients include, but are not limited to, excipients that are found in the Cosmetics, Toiletry, Fragrance Association (CTFA) ingredient Database and the handbook of pharmaceutical excipients such as absorbents, anticaking agents, antioxidants (such as, ascorbic acid, ascorbic acid polypeptide, ascorbyl dipalmitate, BHA, BHT, magnesium ascorbate, magnesium ascorbyl phosphate, propyl gallate sodium ascorbate, sodium ascorbyl/cholesteryl phosphate, sodium bisulfite, sodium erythorbate, sodium metabisulfide, tocopheryl acetate, tocopheryl nicotinate), antistatic agents, astringents, binders, buffering agents, bulking agents, chelating agents, colorants, cosmetic astringents, biocides (such as parabens, organic acids, organic bases, alcohols isothiazolinones and others), deodorant agents, emollients, external analgesics (such as Benzyl Alcohol, Methyl Salicylate, Camphor, Phenol, Capsaicin, Juniper Tar (Menthol, Resorcinol, Methyl Nicotinate, and Turpentine Oil), film formers, flavoring agents, fragrance ingredients, humectants, lytic agents, moisturizing agents, occlusivity enhancers, opacifying agents, oxidizing agents (such as Peroxides, Bromates, Chlorates, Potassium lodates, and Persulfates,), reducing agents (such as Sulfites, Thioglycolates, Cystein, Cysteine HCI, Glutathione, Hydroquinone, Mercaptopropionic Acid, Sulfonates, Thioglycolic Acid), penetration enhancers, pesticides, plasticizers, preservatives, skin bleaching agents such as hydroquinone, skin conditioning agents, skin protectants (such as Allantoin, Aluminum Acetate, Dimethicone, Glycerin, Kaolin, Lanolin, Mineral Oil, Petrolatum, Talc, and Zinc Oxide), slip modifiers, solubilizing agents, solvents, sunscreen agents (such as Aminobenzoic Acid, Cinoxate, cinnamates, Aminobenzoates, Oxybenzone, Red Petrolatum, Titanium Dioxide, and Trolamine Salicylate), surface modifiers, surfactants and emulsifying agents, suspending agents, thickening agents, viscosity controlling agents including increasing or decreasing agents, UV light absorbing agents (such as Acetaminosalol, Allatoin PABA, Benzalphthalide, and Benzophenone,).

Other possible excipients include, but are not limited to, sugars and derivatives (such as acacia, dextrin, dextrose, maltodextrin, and sorbitol), starch derivatives, cellulosic materials (such as methyl cellulose, Ethylcellulose, Hydroxyethylcellulose, Hydroxypropylcellulose, and Hydroxypropylmethylcellulose,), polysaccharides (such as dextrates, guar gum, and xanthan gum), polyethers, suspending agents cyclodextrins, and others.

[0018] Enhancers may also be exemplified by monohydric alcohols such as ethanol and isopropyl, butyl and benzyl alcohols, or dihydric alcohols such as ethylene glycol, diethylene glycol, or propylene glycol, dipropylene glycol and trimethylene glycol, or polyhydric alcohols such as butylene glycol, hexylene glycol, polypropylene glycol, ethylene glycol, and polyethylene glycol, which enhance drug solubility; polyethylene glycol ethers of aliphatic alcohols (such as cetyl, lauryl, oleyl and stearyl) including polyoxyethylene (4) lauryl ether, polyoxyethylene (2) oleyl ether and polyoxyethylene (10) oleyl ether commercially available under the trademark BRIJ® 30, 93 and 97, respectively, from Uniqema Americas LLC (Wilmington, DE), and others such as BRIJ® 35, 52, 56, 58, 72, 76, 78, 92, 96, 700 and 721; vegetable, animal and fish fats and oils such as olive, and castor oils, squalene, lanolin; fatty acids such as oleic, linoleic, and capric acid, and the like; fatty acid esters such as propyl oleate, decyl oleate, isopropyl palmitate, glycol palmitate, glycol laurate, dodecyl myristate, isopropyl myristate and glycol stearate which enhance drug diffusibility; fatty acid alcohols such as oleyl alcohol and its derivatives; fatty acid amides such as oleamide and its derivatives; urea and urea derivatives such as allantoin which affect the ability of keratin to retain moisture; polar solvents such as dimethyldecylphosphoxide, methyloctylsulfoxide, dimethyllaurylamide, dodecylpyrrolidone, isosorbitol, dimethylacetonide, dimethylsulfoxide, decylmethylsulfoxide and dimethylformamide which affect keratin permeability; salicylic acid; amino acids; benzyl nicotinate; and higher molecular weight aliphatic surfactants such as lauryl sulfate salts; and esters of sorbitol and sorbitol anhydride such as polysorbate 20 commercially available under the trademark Tween® 20 from Unigema Americas LLC (Wilmington, DE), as well as other polysorbates such as 21, 40, 60, 61, 65, 80, 81, and 85. Other enhancers include enzymes, panthenol, and other non-toxic enhancers commonly used in transdermal or transmucosal compositions.

[0019] Polyhydric alcohols also include glycols, triols and polyols having 4 to 6 alcoholic hydroxyl groups. Typical of said glycols are glycols containing 2 to 6 carbon atoms, e.g. ethylene glycol, propylene glycol, butylene glycol, polyethylene glycol (average molecular weight about 200-8,000, preferably about 200 to 6,000), etc. Examples of said triols include glycerin, trimethylolpropane, etc. Said polyols are exemplified by sorbitol, polyvinylpyrrolidone, etc. These polyhydric alcohols may be used either singularly or in combination (preferably,

of two or three). Thus, for example, glycerin or dipropylene glycol alone, or a mixture of either glycerin or dipropylene glycol with butylene glycol can be employed.

EXAMPLES

[0020] The following examples are intended to illustrate the invention to one of ordinary skill in the art and should not be interpreted as limiting the scope of the invention set forth in the claims.

Example 1: Preparation of Methacrylate Functional Resin

[0021] About 150 g of a resin composition including about 79% in xylene solution, about 0.076 g of water, and about 0.48 g of 3-methacryloxypropyldimethylchlorosilane (from Gelest Inc., Morrisville, PA) was added to a 16-ounce glass jar. The jar was placed on a rotating wheel to mix for about 20 hours. After about 20 hours, the reaction mixture was analyzed by ¹H NMR, which revealed that more than 99% of chlorosilane was reacted off, indicating that the reaction generated HCI. Accordingly, about 0.92 g of sodium bicarbonate was added to the reaction mixture to neutralize the HCI. After neutralization, the product was filtered through Whatman #2 filter paper in a pressure filter. Xylene was then removed with stripping under full vacuum, followed by drying in a hood at or about room temperature. About 99.12 g of white crystalline product was obtained, which was then dissolved in about 79.1 g of ethyl acetate (from Acros Organics, Geel, Belgium).

[0022] The resulting methacryloxypropyl functionalized resin was the precursor/intermediate used to prepare the silicone acrylate composition of Example 2 below.

Example 2: Preparation of a Silicone Acrylate Composition

[0023] In an 8-ounce jar, a mixture of the following was prepared: about 31.44 g of 2-EHA (from Sigma-Aldrich, St. Louis, MO), about 31.44 g of MA (from Sigma-Aldrich), about 51.37 g of the methacryloxypropyl functionalized resin from Example 1, and about 0.091 g of 2,2'azobis-(2-methylbutyronitrile) (from DuPont, Wilmington, DE). About 85.76 g of the resulting mixture was added to a pear-shaped vessel. The rest of the mix, along with about 102.74 g of ethyl acetate solvent (from Acros Organics), was added to a previously N₂-inerted 3-neck round bottom flask equipped with a stirrer, condenser, and temperature controller. The content of the 3-neck flask then was heated to the reflux temperature of ethyl acetate (about 77 ℃) and held for about one hour. Next, over an about three hour period, the content of the pear-shaped vessel was added to the 3-neck flask while keeping the reaction temperature at or near solvent reflux. The reaction mixture was held at or near reflux temperature for another about 20 hours. The reaction mixture was then cooled to about room temperature. About 200 g of the resulting reaction mixture was added slowly to about 200 g of isopropyl alcohol (IPA). The precipitated material was then separated and dried.

About 70 g of the dried material was then added to ethyl acetate to make an about 42% solution.

Comparative Example 3: Blend of Acrylate Polymer and Silicone PSA preparation

[0024] In an 8-ounce jar, a mixture of the following was prepared: about 31.5 g of 2-EHA (from Sigma-Aldrich), about 31.5 g of MA (from Sigma-Aldrich), about 106.5 g of a silicone adhesive (about 60% ethyl acetate solution), and about 0.091 g of 2,2'azobis-(2-methylbutyronitrile) (from DuPont). About 124.8 g of the resulting mixture was added to a pear-shaped vessel. The rest of the mixture, along with about 126.8 g of ethyl acetate solvent (from Acros Organics), was added to a previously N₂-inerted 3-neck flask equipped with a stirrer, condenser, and temperature controller. The content of the 3-neck flask was then heated to the reflux temperature of ethyl acetate (about 77 ℃) and held for about one hour. Next, over an about three hour period, the content of the pear-shaped vessel was added to the 3-neck flask while keeping the reaction temperature at or near solvent reflux. The reaction mixture was held at or near reflux temperature for another about 20 hours. The reaction mixture was then cooled to about room temperature.

[0025] The reaction mixture was found to separate upon storage, thereby demonstrating that silicone and acrylate adhesive blends generally undergo phase separation when the two components are not compatibilized and/or when they are not covalently linked together. The separation generally occurs even if the acrylate adhesive is prepared in the presence of the silicone adhesive, as described in this example.

Example 4: Addition of Silicone Acrylate Material

[0026] About 1.4 g of the silicone acrylate composition of Example 2 and about 20 g of a blend of acrylate polymer and silicone bio-PSA from Example 3 was thoroughly mixed. The result was a compatibilized blend where the silicone and acrylate components did not separate upon storage or centrifuging.

Comparative Example 5: Preparation of Methacrylate Functional Silicone Bio-PSA

[0027] 150 g of a silicone adhesive including about 60% in ethyl acetate solution, about 0.14 g of water, and about 0.90 g of 3-methacryloxypropyldimethylchlorosilane (from Gelest Inc.) was added to a 16-ounce glass jar. The jar was placed on a rotating wheel to mix for about 20 hours. After about 20 hours, the reaction mixture was analyzed by ¹H NMR, which revealed that more than 99% of chlorosilane was reacted off, indicating that the reaction generated HCI. Accordingly, about 1.72 g of sodium bicarbonate was added to the reaction mixture to neutralize the HCI. After neutralization, the product was filtered through Whatman #2 filter paper in a pressure filter. This resulting methacrylate functional silicone bio-PSA was the intermediate used in Comparative Example 6.

Comparative Example 6: Preparation of Silicone Acrylate Co-Reacted Adhesive

[0028] In an 8-ounce jar, a mixture of the following was prepared: about 31.5 g of 2-EHA (from Sigma-Aldrich), about 31.5 g of MA (from Sigma-Aldrich), about 100 g of methacrylate functional silicone bio-PSA from Example 5 (about 63% ethyl acetate solution), about 14.55 g of ethyl acetate, and about 0.091 g of 2,2'azobis-(2-methylbutyronitrile) (from DuPont). About 133.23 g of the resulting mixture was added to a pear-shaped vessel. The rest of the mixture from the 8-ounce jar, along with about 122.45 g of ethyl acetate solvent (from Acros Organics), was added to a previously N₂-inerted 3-neck flask equipped with a stirrer, condenser, and temperature controller. The content of the 3-neck flask then was heated to the reflux temperature of ethyl acetate (about 77 °C) and held for about one hour. Next, over an about three-hour period, the contents of the pear-shaped vessel were added to the 3-neck flask while keeping the reaction temperature at or near solvent reflux. The reaction mixture was held at or near reflux temperature for another about 20 hours. The reaction mixture was cooled to about room temperature. The covalent bond formation between the acrylate and silicone phase in the reaction mixture assists in preventing the separation of the silicone and acrylate phases.

Example 7: Centrifuge Test

[0029] Centrifuge tubes were filled with materials formed in Example 3, Example 4, and Example 6. All were centrifuged at about 4000 rpm for about 30 minutes in a Sorvall™ ST40 centrifuge (Thermo Scientific, Rochester, NY). Centrifuge testing was used to accelerate the effect of gravity upon storage. The results are compared in the table below.

Table 1

	Comparative Ex.3	Ex.4	Comparative Ex. 6
Before Centrifuge	Uniformly opaque	Uniformly opaque	Uniformly opaque
After Centrifuge	Separate layers of clear material	Uniformly opaque	Uniformly opaque

[0030] Silicone and acrylate adhesives are generally immiscible, and blending them generally results in a thermodynamically unstable mixture that will separate upon storage. The immiscible natures of silicone and acrylate adhesives are indicated by the opaque (as opposed to clear) appearance of the mixture in solvent solution. The results detailed in Table 1 indicate that the immiscible mixture may be stabilized by co-reacting silicone and acrylate adhesive, thereby forming covalent bonds between the two components, as in Comparative Example 6. The immiscible mixture may also be stabilized by adding a compatibilizer (e.g., a silicone acrylate composition) to the mixture, as shown in Example 4. The effectiveness of covalent bonds and compatibilizers is demonstrated by the fact that, after centrifuge treatment (which simulates accelerated storage), the mixture remains uniformly opaque, indicating no or minimal change/separation. The same centrifuge treatment caused the silicone acrylate blend without compatibilizer or covalent bond between the two components

to separate, as indicated by the layers of clear materials comprised of the silicone and acrylate components, respectively.

[0031] The following examples demonstrate the use of resin-acrylate copolymer compositions as PSAs. Also, the potential use in transdermal drug delivery is demonstrated through the loading and release of estradiol from the materials of the following examples.

<u>Example 8</u>: Preparation of Methacrylate Functional Resin (about 0.28 wt% 3-methacryloxypropyldimethylchlorosilane)

[0032] About 200 g of a silicone resin at about 72% solids in xylene and about 100 μL DI water were added to a 500 mL 3-neck flask equipped with an overhead mixer and a dry N₂ inlet and were allowed to mix for approximately 30 minutes, after which about 0.41 g 3-methacryloxypropyldimethylchlorosilane (from Gelest Inc.) was added via a syringe. After approximately 24 hours, the solution was neutralized with about 0.77 g sodium bicarbonate and filtered through Whatman #2 filter paper in a pressure filter. Xylene was then removed with stripping under full vacuum, followed by drying in a hood at room temperature. About 134.0 g of white crystalline product was obtained, which was then dissolved in about 57.4 g of ethyl acetate (from Acros Organics). ¹H NMR confirmed hydrolysis of the chlorosilane and condensation with the resin, resulting in a methacryloxypropyl-functionalized resin.

<u>Example 9</u>: Preparation of Methacrylate Functional Resin (about 0.54 wt% 3-methacryloxypropyldimethylchlorosilane)

[0033] About 200 g of a silicone resin at about 72% solids in xylene and about 100 μ L DI water were added to a 500 mL 3-neck flask equipped with an overhead mixer and a dry N₂ inlet and were allowed to mix for approximately 30 minutes, after which about 0.78 g 3-methacryloxypropyldimethylchlorosilane (from Gelest Inc.) was added via a syringe. After approximately 24 hours, the solution was neutralized with about 1.5 g sodium bicarbonate. After stripping the xylene, about 135.0 g of white crystalline product was obtained, which was then dissolved in about 58.0 g of ethyl acetate (from Acros Organics). ¹H NMR confirmed hydrolysis of the chlorosilane and condensation with the resin, resulting in a methacryloxypropyl-functionalized resin.

[0034] Example 10: Preparation of Methacrylate Functional Resin (about 0.81 wt% 3-methacryloxypropyldimethylchlorosilane)

[0035] About 200 g of a silicone resin at about 72% solids in xylene and about 100 μ L DI water were added to a 500 mL 3-neck flask equipped with an overhead mixer and a dry N₂ inlet and were allowed to mix for approximately 30 minutes, after which about 1.18 g 3-methacryloxypropyldimethylchlorosilane (from Gelest Inc.) was added via a syringe. After approximately 24 hours the solution was neutralized with about 2.4 g sodium bicarbonate. After stripping the xylene, about 126.9 g of white crystalline product was obtained, which was

then dissolved in about 54.3 g of ethyl acetate (from Acros Organics). ¹H NMR confirmed hydrolysis of the chlorosilane and condensation with the resin, resulting in a methacryloxypropyl-functionalized resin.

<u>Example 11</u>: Preparation of Methacrylate Functional Resin (about 1.1 wt% 3-methacryloxypropyldimethylchlorosilane)

[0036] About 200 g of a silicone resin at about 72% solids in xylene and about 100 μ L DI water were added to a 500 mL 3-neck flask equipped with an overhead mixer and a dry N₂ inlet and were allowed to mix for approximately 30 minutes, after which about 1.59 g 3-methacryloxypropyldimethylchlorosilane (from Gelest Inc.) was added via a syringe. After approximately 24 hours, the solution was neutralized with about 3.1 g sodium bicarbonate. After stripping the xylene, about 130.2 g of white crystalline product was obtained, which was then dissolved in about 55.8 g of ethyl acetate (from Acros Organics). ¹H NMR confirmed hydrolysis of the chlorosilane and condensation with the resin, resulting in a methacryloxypropyl-functionalized resin.

[0037] Table 2 below shows the composition analysis, as measured by NMR, of Examples 1, 5, and 8-11.

Examples Protons indicating the presence of components, integral*** Dimethylsilyl of Methacrylate silane Total methacrylate Trimethylsilyl of attached to silicone silicone polymer silicone resin* (M) silane resin (D) H_3C .O_{1/2} .O_{1/2} H_3C H(1), broad, $\delta^{**} = 6.11$ CH3, broad, δ**= CH3, broad, δ^{**} = CH3. broad. $\delta^{**} = 0.08 \text{ ppm}$ 1.94 ppm 0.12-0.15 ppm ppm Example 1 1.8 5 6500 n/a Example 5 7.31 2.8 6515 5160 Example 8 0.19 0.62 1000 n/a Example 9 0.39 1000 1.16 n/a Example 1000 0.58 1.68 n/a 10 Example 11 0.78 2.35 1000 n/a

Table 2

<u>Example 12:</u> Preparation of a Silicone Acrylate Composition from the Methacryloxypropyl-Functionalized Resin of Example 8

[0038] About 37.77 g 2-EHA, about 25.23 g MA, about 30.96 g of the methacryloxypropyl-functionalized resin from Example 8, about 7.25 g ethyl acetate, and about 0.091 g

^{*} The weight ratio of M to Q+TOZ was 1.0 (determined by 29Si-NMR)

^{**} Reference shift CHCl3, δ= 7.27 ppm

^{***} Arbitrary number chosen for largest integral as reference

2,2'azobis-(2-methylbutyronitrile) were added to a 16 oz glass jar and mixed to form a pre-reaction mixture. About 75.9 g of the pre-reaction mixture was added to a 250 mL pear-shaped flask. The rest of the pre-reaction mixture, along with about 102.74 g of ethyl acetate solvent (from Acros Organics), was added to a previously N₂-inerted 3-neck round bottom flask equipped with a stirrer, condenser, and temperature controller. The content of the 3-neck flask then was heated to the reflux temperature of ethyl acetate (about 77 °C) and held for about one hour. Next, over an about three hour period, the content of the pear-shaped vessel was added to the 3-neck flask while maintaining the reaction temperature at or near solvent reflux. The reaction mixture was held at or near reflux temperature for another about 20 hours. The resulting reaction mixture was then cooled to about room temperature. ¹H NMR confirmed the final composition, which is provided in Table 3 below. Approximately 3 g of the resulting reaction mixture was added slowly to about 20 g of methanol. The container was vigorously shaken, and the polymer precipitated from the solution. The precipitated material was then separated and dried. ¹H NMR confirmed the composition of the precipitated material (see Table 3).

<u>Example 13:</u> Preparation of a Silicone Acrylate Composition from the Methacryloxypropyl-Functionalized Resin of Example 9

[0039] About 37.85 g 2-EHA, about 25.24 g MA, about 30.89 g of the methacryloxypropylfunctionalized resin from Example 9, about 7.44 g ethyl acetate, and about 0.087 g 2,2'azobis-(2-methylbutyronitrile) were added to a 16 oz glass jar and mixed to form a prereaction mixture. About 76.1 g of the pre-reaction mixture was added to a 250 mL pearshaped flask. The rest of the pre-reaction mixture, along with about 98.8 g of ethyl acetate solvent (from Acros Organics), was added to a previously N2-inerted 3-neck round bottom flask equipped with a stirrer, condenser, and temperature controller. The content of the 3neck flask then was heated to the reflux temperature of ethyl acetate (about 77 °C) and held for about one hour. Next, over an about three hour period, the content of the pear-shaped vessel was added to the 3-neck flask while maintaining the reaction temperature at or near solvent reflux. The reaction mixture was held at or near reflux temperature for another about 20 hours. The reaction mixture was then cooled to about room temperature. ¹H NMR confirmed the final composition, which is provided in Table 3 below. Approximately 3 g of the resulting reaction mixture was added slowly to about 20 g of methanol. The container was vigorously shaken, and the polymer precipitated from the solution. The precipitated material was then separated and dried. 1H NMR confirmed the composition of the precipitated material (see Table 3).

<u>Example 14:</u> Preparation of a Silicone Acrylate Composition from the Methacryloxypropyl-Functionalized Resin of Example 10

[0040] About 37.83 g 2-EHA, about 25.19 g MA, about 31.08 g of the methacryloxypropylfunctionalized resin from Example 10, about 7.21 g ethyl acetate, and about 0.086 g 2,2'azobis-(2-methylbutyronitrile) were added to a 16 oz glass jar and mixed to form a prereaction mixture. About 74.8 g of the pre-reaction mixture was added to a 250 mL pearshaped flask. The rest of the pre-reaction mixture, along with about 98.9 g of ethyl acetate solvent (from Acros Organics), was added to a previously N₂-inerted 3-neck round bottom flask equipped with a stirrer, condenser, and temperature controller. The content of the 3neck flask then was heated to the reflux temperature of ethyl acetate (about 77 °C) and held for about one hour. Next, over an about three hour period, the content of the pear-shaped vessel was added to the 3-neck flask while maintaining the reaction temperature at or near solvent reflux. The reaction mixture was held at or near reflux temperature for another about 20 hours. The reaction mixture was then cooled to about room temperature. ¹H NMR confirmed the final composition, which is provided in Table 3 below. Approximately 3 g of the resulting reaction mixture was added slowly to about 20 g of methanol. The container was vigorously shaken and the polymer precipitated from the solution. The precipitated material was then separated and dried. 1H NMR confirmed the composition of the precipitated material (see Table 3).

<u>Example 15:</u> Preparation of a Silicone Acrylate Composition from the Methacryloxypropyl-Functionalized Resin of Example 11

[0041] About 38.02 g 2-EHA, about 25.17 g MA, about 31.04 g of the methacryloxypropylfunctionalized resin from Example 11, about 7.12 g ethyl acetate, and about 0.090 g 2,2'azobis-(2-methylbutyronitrile) were added to a 16 oz glass jar and mixed to form a prereaction mixture. About 75.3 g of the pre-reaction mixture was added to a 250 mL pearshaped flask. The rest of the pre-reaction mixture, along with about 99.3 g of ethyl acetate solvent (from Acros Organics), was added to a previously N2-inerted 3-neck round bottom flask equipped with a stirrer, condenser, and temperature controller. The content of the 3neck flask then was heated to the reflux temperature of ethyl acetate (about 77 °C) and held for about one hour. Next, over an about three hour period, the content of the pear-shaped vessel was added to the 3-neck flask while maintaining the reaction temperature at or near solvent reflux. The reaction mixture was held at or near reflux temperature for another about 20 hours. The reaction mixture was then cooled to about room temperature. ¹H NMR confirmed the final composition, which is provided in Table 3 below. Approximately 3 g of the resulting reaction mixture was added slowly to about 20 g of methanol. The container was vigorously shaken and the polymer precipitated from the solution. The precipitated material was then separated and dried. 1H NMR confirmed the composition of the precipitated material (see Table 3).

Table 3

Example	Condition	%ЕНА	%MA	%Silicone Resin	% Residual monomer
Example 12	before precipitation	44.7	28.7	25.7	0.94
	after precipitation	52.3	34.2	13.5	0
Example 13	before precipitation	44.1	28.9	25.7	1.24
	after precipitation	49.8	32.4	17.8	0.09
Example 14	before precipitation	44.5	28.9	25.6	1
	after precipitation	49.1	32.1	18.8	0.07
Example 15	before precipitation	40	25.6	26.7	7.48
	after precipitation	47.8	31	20.5	0.72

Comparative Example 16: Preparation of an Acrylate Composition

[0042] About 50.48 g 2-EHA, about 33.70 g MA, about 16.09 g ethyl acetate, and about 0.115 g 2,2'azobis-(2-methylbutyronitrile) were added to a 16 oz glass jar and mixed to form a pre-reaction mixture. About 75.0 g of the pre-reaction mixture was added to a 250 mL pear-shaped flask. The rest of the pre-reaction mixture, along with about 100.0 g of ethyl acetate solvent (from Acros Organics), was added to a previously N₂-inerted 3-neck round bottom flask equipped with a stirrer, condenser, and temperature controller. The content of the 3-neck flask then was heated to the reflux temperature of ethyl acetate (about 77 °C) and held for about one hour. Next, over an about three hour period, the content of the pear-shaped vessel was added to the 3-neck flask while keeping the reaction temperature at or near solvent reflux. The reaction mixture was held at or near reflux temperature for another about 20 hours. The reaction mixture was then cooled to about room temperature.

Example 17: Tape Properties of the Compositions of Examples 12-16

[0043] The resulting compositions of Examples 12-16 were coated onto both 2 mil and 10 mil polyester using a film applicator and dried for about 5 minutes at room temperature followed by heating for about 5 minutes at about 110 ℃, resulting in a film thickness of about 1 mil. Static shear was performed by adhering the samples (having an about 1 x 1 inch contact area) to stainless steel panels. Weights (1 kg) were hung from the samples, and the time to cohesive failure at about room temperature was monitored (using ASTM D3654M and/or PSTC-7). Probe tack testing was performed with a TA Texture Analyzer using a 7 mm, stainless steel punch probe with a 1 inch radius of curvature. Samples were placed under the indexable brass plate to position them for analysis. The following program settings were used: pre-test speed of about 0.5 mm/sec, test speed of about 0.2 mm/sec, post-test

speed of about 0.2 mm/sec, test force of about 100 g, dwell time of about 0.5 seconds, trigger force of about 1.0 g, auto trigger mode, and collection rate of about 200 points/second. The average of five measurements is reported in Table 4 below.

Table 4

Sample	Static Shear 2.2 psi, n=3 (min)	Tack Peak force n=5 (g)	Tack peak area n=5 (g.sec)
Example 12	162.0 ± 17.7	129.1 ± 5.8	144.1 ± 9.1
Example 13	4085.3 ± 922.1	138.5 ± 14.4	58.6 ± 13.9
Example 14	>14,300	113.6 ± 18.1	39.8 ± 11.9
Example 15	>14,300	150.2 ± 19.2	51.4 ± 12.5
Comparative Example 16	38.1 ± 9.4	100.8 ± 17.9	87.7 ± 24.6

[0044] These results show that the increase in methacryloxypropyl-functionality on the silicone resin increased the shear properties of the material without substantially influencing the tack. However, with this increase in the cohesive nature of the material, the adhesive failure mechanism is changed, as shown by the decrease in the tack peak area, which indicates reduction in fibrillation. Therefore, the copolymerization of (meth)acrylate-functional silicone resin with (meth)acrylate monomers can be utilized to create resinacrylate PSA with modified properties over that of acrylic PSA.

Examples 17-21: Estradiol-loaded Formulations

[0045] Example 17 was prepared by adding about 0.3865 g Kollidon K25 PVP and about 0.0774 g estradiol to a scintillation vial. To this, about 0.4650 g ethyl acetate was added to disperse the powders followed by the addition of about 0.2337 g isopropyl alcohol to dissolve the powders. To this solution, about 8.7188 g of the resin-acrylate composition of Example 12, about 0.7501 g of oleic acid / dipropylene glycol (about 1.5:1 w/w), and about 0.897 g ethyl acetate were added and mixed. The scintillation vial was placed on a vial roller and mixed for about 24 hours. After mixing, the formulation was cast onto about 2 mil thick polyester using a film applicator and dried for about 5 minutes at or about room temperature followed by heating for about 5 minutes at about 92 °C to achieve a final coat weight of about 10 mg/cm². The films were then covered with a fluorocarbon coated release liner. Examples 18-21 were prepared in a similar fashion except that the composition of Example 12 was substituted with the composition of Example 13 for Example 18, the composition of Example 14 for Example 19, the composition of Example 15 for Example 20, the composition of Comparative Example 16 for Comparative Example 20. The components of each of Examples 17-21 are listed in Table 5 below.

Table 5

Materials	Example	Example	Example	Example	Comparative
	17	18	19	20	Example 21
Kollidon K25 PVP (g)	0.3865	0.3867	0.3864	0.3866	0.3867

Estradiol (g)	0.0774	0.0776	0.0777	0.0779	0.0777
Oleic acid / Dipropylene glycol (1.5:1 w/w) (g)	0.7501	0.7500	0.7535	0.7509	0.7509
Example12 (g)	8.7188				
Example 13 (g)		8.6366			
Example 14 (g)			8.8993		
Example 15 (g)				9.8866	
Comparative Example 16 (g)					9.0679
Ethyl Acetate (g)	1.3620	1.9074	1.8296	0.6635	1.3683
Isopropyl alcohol (g)	0.2337	0.2351	0.2369	0.2406	0.2323

Example 22: Estradiol Flux

[0046] Patches having a surface area of about 0.495 cm² were fluxed (n=3) through heat separated epidermis from full-thickness human cadaver skin. The receptor fluid was phosphate buffered saline having a pH of about 7.4, and the study was conducted at about 32 °C. Samples of the receptor fluid were taken at about 8, 16, 24, 36, 48, 60, 72 and 84 hours with full replacement using fresh phosphate buffered saline. Samples were analyzed for estradiol concentration using an appropriate UPLC method, and the results are reported in Table 6 below and in FIG. 1.

Table 6

Sample	Cumulative Release 84 hr,	Cumulative Release, n=3
	n=3	(%)
	(μg/cm²)	
Example 17	41.14 ± 17.23	24.01 ± 10.06
Example 18	10.40 ± 1.88	7.08 ± 1.28
Example 19	21.33 ± 5.64	14.91 ± 3.95
Example 20	12.64 ± 3.67	8.26 ± 2.4
Comparative Example 21	11.06 ± 0.58	7.09 0.37

[0047] These results indicate the copolymerization of (meth)acrylate-functional silicone resin with (meth)acrylate monomers can be utilized to create resin-acrylate PSA with modified drug release properties over that of acrylic PSA.

Example 23: Preparation of a Silicone Acrylate film former Composition

[0048] About 7.5 g methyl methacrylate, about 5 g butyl acrylate, about 7.5 g of the methacryloxypropyl-functionalized resin from Example 9, about 50 g ethyl acetate, and about 0.087 g 2,2'azobis-(2-methylbutyronitrile) were added to a 16 oz glass jar and mixed to form a pre-reaction mixture. The pre-reaction mixture was added to a previously N₂-inerted 3-neck round bottom flask equipped with a stirrer, condenser, and temperature controller. About 22.5 g methyl methacrylate, about 15 g Butyl acrylate, about 22.5 g of the methacryloxypropyl-functionalized resin from Example 9, and about 112 g ethyl acetate were added to a 16 oz glass jar and mixed to form a feed mixture. The feed mixture was then transferred to a 250 mL pear-shaped flask. About 17 g of ethyl acetate and about 0.6 g of

2,2'azobis-(2-methylbutyronitrile) were added to a 2 oz glass vial and mixed to form a initiator mixture. The initiator mixture was then transferred to a syringe assembled on a syringe pump. The content of the 3-neck flask then was heated to the reflux temperature of ethyl acetate (about 77 °C) and held for about 15 minutes. Over an about two hour period, the content of the pear-shaped vessel was added to the 3-neck flask while maintaining the reaction temperature at or near solvent reflux. Simultaneously, over an about four hour period, the initiator mixture of the syringe pump was added. The reaction mixture was held at or near reflux temperature for another about 16 hours. The reaction mixture was then cooled to about room temperature. ¹H NMR confirmed the final composition, which was determined after all volatile components evaporated from the film former: 43.3 % polymerized methylmethacrylate, 26.3 % polymerized butyl acrylate, and 30.4 % silicone resin. The material was cast, the solvent dried, and non-tacky film continuous film formed. [0049] While the invention is susceptible to various modifications and alternative forms, specific embodiments have been shown by way of example in the examples and described in detail herein. It should be understood, however, that the invention is not intended to be limited to the particular forms disclosed. Rather, the invention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.

Claims:

1. A silicone acrylate composition having a general formula:

wherein

each R1 is independently selected from hydrogen or methyl;

each R² and R³ is independently selected from hydrogen, hydrogen alkyls, branched alkyls, methyl, ethyl, propyl, n-butyl, iso-butyl, tert-butyl, hexyl, 2-ethylhexyl, iso-octyl, isononyl, iso-pentyl, tridecyl, stearyl, lauryl, hydroxyethyl acetate, (hydroxyethyl)methacrylate, methacrylate esters, and acrylate esters; and

each R4 is a silane having the general formula:

$$R^{8} - Si - R^{5}$$

wherein R^5 is selected from $(CH_2)_z$ -O-, $-(CH_2)_3$ -NH-C(=O)-O-CH₂-CH₂-, $-(CH_2)_3$ -NH-CH₂-CH(OH)-CH₂-, and $-OCH_2$ -CH₂-, and

each R^6 , R^7 , and R^8 is independently selected from C1-C12 alkyl, -O-(Si-O)p-Si(CH₃)₃ where p is from 0 to 1000, phenyl, and -(CH₂)_n-CH=CH₂ where n is from 0 to 6.

2. The silicone acrylate composition of claim 1, wherein R⁴ has the formula

3. The silicone acrylate composition of claim 1, wherein each R is a silsesquioxane having the general formula:

$$[(R^9)_2R^{10}SiO_{1/2}]_a[SiO_{4/2}]_a[R^{11}SiO_{3/2}]_t[(R^{12})_3SiO_{1/2}]_m$$


wherein R⁹ is selected from C1-C12 alkyl, -O-(Si-O)p-Si(CH₃)₃ where p is from 0-200, phenyl, and -(CH₂)_n-CH=CH₂ where n is between 0 and 6,

 R^{10} is selected from -(CH₂)_z-, -(CH₂)₃-NH-C(=O)-O-CH₂-CH₂-, -(CH₂)₃-NH-CH₂-CH(OH)-CH₂-, and -OCH₂-CH₂-,

 R^{11} is selected from phenyl, C1-C12 alkyl, -OH, isopropoxy, and -(CH₂)_n-CH=CH₂ where n is between 0 and 6, and

R¹² is selected from C1-C12 alkyl.

- 4. The silicone acrylate composition of claim 3, wherein a is from 1 to 5 per R unit, q is from 1 to 300, t is from 0-300, m is from 4-300, and the ratio of m/q is between about 10/90 to about 90/10.
- 5. The silicone acrylate composition of claim 1, wherein the composition includes between about 0-99% w/w x groups, between about 0-99% w/w y groups, between about 0-20% w/w s groups, and between about 1-80% w/w r groups, where the % w/w of at least one of the x groups and the y groups is not zero.
- 6. A thermodynamically stable silicone acrylate blend composition comprising:
 - (a) a silicone acrylate composition having a general formula:



wherein

each R¹ is independently selected from hydrogen or methyl,

each R² and R³ is independently selected from hydrogen, hydrogen alkyls, branched alkyls, methyl, ethyl, propyl, n-butyl, iso-butyl, tert-butyl, hexyl, 2-ethylhexyl, iso-octyl, iso-nonyl, iso-pentyl, tridecyl, stearyl, lauryl, hydroxyethyl acetate, (hydroxyethyl)methacrylate, methacrylate esters, and acrylate esters, and

each R4 is a silane having the general formula

wherein R⁵ is selected from $(CH_2)_z$ -O-, - $(CH_2)_3$ -NH-C(=O)-O-CH₂-CH₂-, - $(CH_2)_3$ -NH-CH₂-CH(OH)-CH₂-, and -OCH₂-CH₂-, and

each R^6 , R^7 , and R^8 is independently selected from C1-C12 alkyl, -O-(Si-O)p-Si(CH₃)₃ where p is from 0 to 1000, phenyl, and -(CH₂)_n-CH=CH₂ where n is from 0 to 6;

- (b) a silicone pressure sensitive adhesive; and
- (c) an acrylic polymer,

wherein the silicone acrylate blend composition lacks covalent bonds between the composition, the silicone pressure sensitive adhesive, and the acrylic polymer.

- 7. The silicone acrylate blend composition of claim 6, wherein the silicone pressure sensitive adhesive is selected from amine-compatible silicone adhesives and any combination thereof.
- 8. The silicone acrylate blend composition of claim 6, wherein the pressure sensitive adhesive has the general formula:

$$[SiO_{4/2}]_9[R^{13}SiO_{3/2}]_h[(R^{14})_3SiO_{1/2}]_i[(R^{14})_3SiO_{2/2}]_d,$$

wherein R¹³ is –OH, isopropoxy, or the combination thereof, and R¹⁴ is C1-C12 alkyl.

- 9. The silicone acrylate blend composition of claim 6, wherein g is between about 5-50 mol%, h is between about 0.1-20 mol%, i is between about 5-50 mol%, and d is between about 5-90%, and wherein the weight ratio of (g+h+i)/d is between about 10/90 to about 90/10.
- 10. The silicone acrylate blend composition of any one of claims 6-9, wherein the silicone pressure sensitive adhesive is (a) silanol-functional or (b) capped with hexamethyldisilazane.
- 11. The silicone acrylate blend composition of claims 6-10, wherein the acrylic polymer is an acrylic polymer compound selected from aliphatic acrylates, aliphatic methacrylates, cycloaliphatic acrylates, cycloaliphatic methacrylates, acrylamides, methacrylamides, hydroxy-functional (meth)acrylates, carboxy-functional (meth)acrylates, and any combination thereof, each of said acrylic monomer compounds having up to 20 carbon atoms in the alkyl radical.
- 12. The silicone acrylate blend composition of claim 11, wherein the acrylic monomer includes aliphatic acrylates selected from methyl acrylate, ethyl acrylate, propyl acrylate, n-butyl acrylate, iso-butyl acrylate, tert-butyl acrylate, hexyl acrylate, 2-ethylhexyl acrylate, iso-octyl acrylate, iso-nonyl acrylate, iso-pentyl acrylate, tridecyl acrylate, stearyl acrylate, lauryl acrylate, and any combination thereof,
- 13. The silicone acrylate blend composition of claim 11, wherein the acrylic monomer includes aliphatic methacrylates selected from methyl methacrylate, ethyl methacrylate, propyl methacrylate, n-butyl methacrylate, iso-butyl methacrylate, tert-butyl methacrylate, hexyl methacrylate, 2-ethylhexyl methacrylate, iso-octyl methacrylate, iso-nonyl

methacrylate, iso-pentyl methacrylate, tridecyl methacrylate, stearyl methacrylate, lauryl methacrylate, and any combination thereof.

14. A transdermal drug delivery system, comprising:a silicone acrylate blend composition having a general formula:

wherein

each R¹ is independently selected from hydrogen or methyl,

each R² and R³ is independently selected from hydrogen, hydrogen alkyls, branched alkyls, methyl, ethyl, propyl, n-butyl, iso-butyl, tert-butyl, hexyl, 2-ethylhexyl, iso-octyl, iso-nonyl, iso-pentyl, tridecyl, stearyl, lauryl, hydroxyethyl acetate, (hydroxyethyl)methacrylate, methacrylate esters, and acrylate esters, and

each R4 is a silane having the general formula

$$\begin{array}{c}
R^{6} \\
 \\
R \\
 \\
Si \\
 \\
R^{7}
\end{array}$$

wherein R⁵ is selected from (CH₂)z-O-, -(CH₂)₃-NH-C(=O)-O-CH₂-CH₂-, -(CH₂)₃-NH-CH₂-CH(OH)-CH₂-, and -OCH₂-CH₂-, and

each R^6 , R^7 , and R^8 is independently selected from C1-C12 alkyl, -O-(Si-O)p-Si(CH₃)₃ where p is from 0 to 1000, phenyl, and -(CH₂)_n-CH=CH₂ where n is from 0 to 6;

an active agent for controlled transdermal delivery to a substrate;

optionally, one or more penetration enhancers; and

optionally, one or more polymers configured to prevent crystallization of the active agent.




FIGURE 1

INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

C08F 230/08(2006.01)i, C08F 220/10(2006.01)i, A61K 47/32(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C08F 230/08; A61K 47/34; C08L 83/04; A61K 31/56; C09J 7/02; C09D 183/04; A61K 9/70; C09J 4/00; C09J 183/10; C08F 220/10;
A61K 47/32

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) eKOMPASS (KIPO internal) & Keywords: silicone PSA, pressure sensitive adhesive, silane, silsesquioxane, transdermal drug delivery, 3-methacryloxypropyldimethylchlorosilane

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2009-0196911 A1 (LOUBERT, GARY L. et al.) 06 August 2009 See abstract; claims 1, 11-18, 31; and paragraphs [0028]-[0029], [0031], [0053]-[0062].	1-5,14
Y	[0000] [0002].	6-10
X	US 2012-0108560 A1 (EVANS, CHANA WILSON et al.) 03 May 2012 See claim 15; paragraphs [0015]-[0016] and [0055].	1-5,14
Y	oce craim to, paragrapho footol footol and footol.	6-10
A	WO 92-20751 A1 (MINNESOTA MINING AND MANUFACTURING COMPANY) 26 November 1992 See claims 1, 6-7.	1-10,14
A	EP 1076081 A1 (3M INNOVATIVE PROPERTIES COMPANY) 14 February 2001 See abstract; paragraphs [0037]-[0038].	1-10,14
A	WO 2007-050580 A2 (DOW CORNING CORPORATION) 03 May 2007 See claims 1, 9.	1-10,14

* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" artificial date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "B" document published prior to the international filing date "B" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other means "O" document referring to an oral disclosure, use, exhibition or other than the priority date claimed "B" document published prior to the international filing date but later than the priority date claimed "B" document published prior to the international filing date but later than the priority date claimed "B" Date of mailing of the international search report O4 July 2016 (04.07.2016) Date of mailing of the international search report			
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of the actual completion of the international search The document defining the general state of the art which is not considered to be of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family Date of mailing of the international search report		Further documents are listed in the continuation of Box C.	See patent family annex.
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report	*	Special categories of cited documents:	"T" later document published after the international filing date or priority
to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family Date of mailing of the international search report	"A"	document defining the general state of the art which is not considered	
"E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document of particular relevance; the claimed invention cannot be considered novel or cannot b		to be of particular relevance	**
filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search filing date considered novel or cannot be considered to involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family Date of mailing of the international search report	"E"	earlier application or patent but published on or after the international	
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report		** *	• •
cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report	"L"	e e e e e e e e e e e e e e e e e e e	***************************************
special reason (as specified) document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report		• • • • • • • • • • • • • • • • • • • •	•
"O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report		<u>.</u>	
means document published prior to the international filing date but later than the priority date claimed being obvious to a person skilled in the art document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report	"O"		•
"P" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report		, ,	· · · · · · · · · · · · · · · · · · ·
than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report	"P"		•
Date of the actual completion of the international search Date of mailing of the international search report	-	1 1	a document member of the same patent family
		1 7	
04 July 2016 (04.07.2016) 04 July 2016 (04.07.2016)	Date	of the actual completion of the international search	Date of mailing of the international search report
		04 July 2016 (04.07,2016)	04 July 2016 (04.07.2016)

Name and mailing address of the ISA/KR
International Application Division
Korean Intellectual Property Office
189 Cheongsa-ro, Seo-gu, Daejeon, 35208, Republic of Korea

KIM, Dong Seok

Dong Seok

Telephone No. +82-42-481-5405

Facsimile No. +82-42-481-8578

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/015500

Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This interna	tional search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
	aims Nos.: cause they relate to subject matter not required to be searched by this Authority, namely:
be ex	aims Nos.: 12-13 cause they relate to parts of the international application that do not comply with the prescribed requirements to such an tent that no meaningful international search can be carried out, specifically: ach of claims 12 and 13 refers to a claim which is not drafted in accordance with the third sentence of Rule 6.4(a).
~	aims Nos.: 11 cause they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This Interna	tional Searching Authority found multiple inventions in this international application, as follows:
	all required additional search fees were timely paid by the applicant, this international search report covers all searchable ims.
	all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment any additional fees.
	only some of the required additional search fees were timely paid by the applicant, this international search report covers ly those claims for which fees were paid, specifically claims Nos.:
	required additional search fees were timely paid by the applicant. Consequently, this international search report is tricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark or	The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee. The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2016/015500

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2009-0196911 A1	06/08/2009	CN 101501088 A	05/00/2000
US 2009-0190911 A1	00/08/2009	CN 101501088 A CN 101501088 B	05/08/2009 30/11/2011
		DK 2024406 T3	05/11/2011
		EP 2024406 A2	18/02/2009
		EP 2024406 B1	01/08/2012
		JP 05654100 B2	14/01/2015
		JP 2009-540052 A	19/11/2009
		JP 2014-015614 A	30/01/2014
		KR 10-1432698 B1	22/08/2014
		KR 10-2009-0025238 A	10/03/2009
		US 8124689 B2	28/02/2012
		WO 2007-145996 A2	21/12/2007
		WO 2007-145996 A3	19/06/2008
		WO 2007-145996 A9	14/02/2008
US 2012-0108560 A1	03/05/2012	US 8569416 B2	29/10/2013
WO 92-20751 A1	26/11/1992	AU 2008792 A	30/12/1992
	20, 11, 1002	AU 2011092 A	30/12/1992
		AU 662157 B2	24/08/1995
		BR 9206038 A	02/08/1994
		BR 9206039 A	02/08/1994
		CA 2103359 A1	24/11/1992
		CA 2109712 A1	26/11/1992
		DE 69221148 T2	29/01/1998
		EP 0587752 A1	23/03/1994
		EP 0587752 B1	23/07/1997
		EP 0593514 A1 ES 2104933 T3	27/04/1994 16/10/1997
		KR 10-0210735 B1	15/07/1999
		KR 10-1994-0701048 A	22/04/1994
		MX 9202411 A1	01/11/1992
		MY 131182 A	31/07/2007
		US 05308887 A	03/05/1994
		US 05464659 A	07/11/1995
		US 05624763 A	29/04/1997
		WO 92-20752 A1	26/11/1992
EP 1076081 A1	14/02/2001	AU 6994700 A1	19/03/2001
		DE 60006399 T2	09/09/2004
		EP 1208180 A1	29/05/2002
		EP 1208180 B1	05/11/2003
		ES 2209966 T3	01/07/2004
		WO 01-14486 A1	01/03/2001
WO 2007-050580 A2	03/05/2007	EP 1940368 A2	09/07/2008
		WO 2007-050580 A3	20/09/2007